NCT03381287View on ClinicalTrials.gov

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 13, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Hypercholesterolemia
Interventions
DRUG

HTD1801 Tablets, 500 mg

500 mg/day (250 mg BID)

DRUG

HTD1801 Tablets, 1000 mg

1000 mg/day (500 mg BID)

DRUG

HTD1801 Tablets, 2000 mg

2000 mg/day (1000 mg BID)

DRUG

Placebo to match 500 mg HTD1801

2 tablets/day (1 tablet BID)

DRUG

Placebo to match 1000 mg HTD1801

4 tablets/day (2 tablet BID)

DRUG

Placebo to match 2000 mg HTD1801

8 tablets/day (4 tablet BID)

Trial Locations (3)

4006

Q-Pharm Pty Ltd., Herston

5000

CMAX Clinical Research Pty Ltd, Adelaide

6009

Linear Clinical Research, Nedlands

All Listed Sponsors
lead

HighTide Biopharma Pty Ltd

INDUSTRY

NCT03381287 - A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia | Biotech Hunter | Biotech Hunter